Stock Analyses

Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.

All sectors 6,479 Financial Services 1,900 Healthcare 1,116 Technology 1,079 Industrials 668 Consumer Cyclical 490 Basic Materials 337 Consumer Defensive 248 Communication Services 213 Utilities 183 Energy 165 Real Estate 80

1,116 stocks · page 13 of 19

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

enVVeno Medical Corp

NOVO NORDISK A S

Deeply undervalued

Model IV$212.96

Discount 36% Return to IV: +55.3%

Owner yield 5.5% 10-yr IRR 10.5% · moderate

Market implies +0.6%/yr vs model +7.4% · below model

Envista Holdings Corp

Deeply overvalued

Premium +48% Return to IV: -32.5%

Owner yield 5.7% 10-yr IRR 9.7% · steady

Market implies +10.4%/yr vs model +5.6% · above model

Market implies -50.0%/yr vs model +50.0% · below model

Market implies -50.0%/yr vs model +50.0% · below model

Nexalin Technology, Inc.

Market implies +111.9%/yr vs model +20.3% · above model

Nexentis Technologies Inc.

Market implies +31.2%/yr vs model +15.0% · above model

Orchestra BioMed Holdings, Inc.

Market implies +44.1%/yr vs model +15.0% · above model

Market implies +70.9%/yr vs model +15.0% · above model

Oculis Holding AG

Oculis Holding AG

OCULAR THERAPEUTIX, INC

Market implies +55.6%/yr vs model +4.5% · above model

Odyssey Therapeutics, Inc.

Orthofix Medical Inc.

Deeply undervalued

Discount 83% Return to IV: +487.5%

Market implies -34.7%/yr vs model +15.4% · below model

Market implies +48.4%/yr vs model +15.0% · above model

ORGANIGRAM GLOBAL INC.

Deeply undervalued

Discount 46% Return to IV: +85.7%

Owner yield 17.3% 10-yr IRR 26.3% · steady

Market implies -6.0%/yr vs model +3.0% · below model

OnKure Therapeutics, Inc.

OKYO Pharma Ltd

Olema Pharmaceuticals, Inc.

Outset Medical, Inc.

Omada Health, Inc.

Deeply undervalued

Discount 64% Return to IV: +178.1%

Market implies -18.2%/yr vs model +45.6% · below model

BeOne Medicines Ltd.

Market implies +22.7%/yr vs model +46.0% · below model

Onconetix, Inc.

Discount 1% Return to IV: +1.1%

Market implies -3.5%/yr vs model +15.0% · below model

ONCOLYTICS BIOTECH INC

ONTO INNOVATION INC.

Owner yield 1.6% 10-yr IRR -7.6% · steady

Market implies +30.8%/yr vs model +3.0% · above model

Option Care Health, Inc.

Deeply undervalued

Discount 51% Return to IV: +106.0%

Owner yield 7.1% 10-yr IRR 20.3% · grower

Market implies +2.3%/yr vs model +14.8% · below model

OPKO HEALTH, INC.

Deeply overvalued

Premium +267% Return to IV: -72.8%

Market implies +15.8%/yr vs model +2.0% · above model

Optimi Health Corp.

SYNTEC OPTICS HOLDINGS, INC.

Market implies +47.4%/yr vs model +2.0% · above model

SYNTEC OPTICS HOLDINGS, INC.

Optex Systems Holdings Inc

Deeply undervalued

Discount 53% Return to IV: +111.2%

Owner yield 3.2% 10-yr IRR 8.9% · grower

Market implies +4.4%/yr vs model +22.9% · below model

Origin Materials, Inc.

Market implies -50.0%/yr vs model +8.0% · below model

Organogenesis Holdings Inc.

Deeply undervalued

Discount 58% Return to IV: +137.0%

Market implies -12.9%/yr vs model +4.8% · below model

Oric Pharmaceuticals, Inc.

Oruka Therapeutics, Inc.

ORAMED PHARMACEUTICALS INC.

Market implies +85.4%/yr vs model +2.0% · above model

OSR Holdings, Inc.

Market implies +10.9%/yr vs model +15.0% · below model

OSR Holdings, Inc.

Deeply undervalued

Discount 88% Return to IV: +750.0%

Market implies -37.5%/yr vs model +15.0% · below model

OS Therapies Inc

ORASURE TECHNOLOGIES INC

Market implies +17.8%/yr vs model +2.0% · above model

Outlook Therapeutics, Inc.

Market implies +42.2%/yr vs model +15.0% · above model

Ovid Therapeutics Inc.

Market implies +75.8%/yr vs model +2.0% · above model

Deeply overvalued

Premium +112% Return to IV: -52.9%

Market implies +12.4%/yr vs model +8.7% · above model

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Market implies +40.8%/yr vs model +5.2% · above model

PACS Group, Inc.

Deeply undervalued

Model IV$183.29

Discount 77% Return to IV: +335.5%

Market implies -0.4%/yr vs model +24.1% · below model

PHIBRO ANIMAL HEALTH CORP

Deeply overvalued

Premium +75% Return to IV: -43.0%

Owner yield 1.1% 10-yr IRR -5.8% · moderate

Market implies +15.5%/yr vs model +11.2% · above model

PALISADE BIO, INC.

Market implies +91.3%/yr vs model +15.0% · above model

Park Dental Partners, Inc.

Passage BIO, Inc.

Market implies +91.1%/yr vs model +2.0% · above model

Prestige Consumer Healthcare Inc.

Deeply undervalued

Model IV$126.70

Discount 63% Return to IV: +171.4%

Owner yield 10.7% 10-yr IRR 18.1% · steady

Market implies -8.7%/yr vs model +4.1% · below model

PSYENCE BIOMEDICAL LTD.

PSYENCE BIOMEDICAL LTD.

PUMA BIOTECHNOLOGY, INC.

Discount 9% Return to IV: +9.4%

Owner yield 7.8% 10-yr IRR 12.0% · steady

Market implies +0.4%/yr vs model +3.0% · in line

Pacira BioSciences, Inc.

Deeply undervalued

Discount 58% Return to IV: +139.0%

Owner yield 13.3% 10-yr IRR 25.9% · moderate

Market implies -5.2%/yr vs model +8.3% · below model